Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial
- 352 Downloads
Despite established links between nicotine dependence and depression, little research has examined the effects of nicotine on depression symptoms.
This study evaluated the acute and chronic effects of transdermal nicotine in nonsmokers with baseline depression symptoms during a 4-week, double-blind, placebo-controlled trial.
Nonsmokers with scores ≥10 on the Center for Epidemiological Studies Depression scale (CES-D) were recruited from the community. Mood and cognitive performance were measured at baseline (day 0) and at 1, 8, 21, and 28 days. Participants were randomly assigned to wear a placebo or nicotine patch for 4 weeks (3.5 mg/day during weeks 1 and 4; 7 mg/day during weeks 2 and 3). The final sample consisted of 11 nonsmokers with a mean baseline CES-D score of 27.36 (SD=10.53).
Salivary nicotine levels indicated the majority of participants were compliant with treatment. Acute nicotine did not alter mood. After adjusting for baseline values, chronic nicotine resulted in a significant decline in CES-D scores at day 8 (3.5 mg/day), but returned to placebo levels by the last visit. This return to baseline levels was coincident with a decrease in nicotine administration from 7 to 3.5 mg/day. A similar trend for improved response inhibition as measured by the Conners Continuous Performance Task was also observed. Reported side effects were infrequent and minimal.
These findings suggest a role for nicotinic receptor systems in the pathophysiology of depression and that nicotinic compounds should be evaluated for treating depression symptoms.
KeywordsCognitive performance Depression Nicotine Mood
This research was supported by a Young Investigator Award from the National Alliance for Research on Schizophrenia and Depression. Dr. Rose is an inventor named on several nicotine patch patents and receives royalties from sales of certain nicotine patches.
- Belluardo N, Mudo G, Blum M, Amato G, Fuxe K (2000) Neurotrophic effects of central nicotinic receptor activation. J Neural Transm Suppl:227–245Google Scholar
- Conners CK (1994) The Conners Continuous Performance Test. Multi-Health Systems, Inc., Toronto, CanadaGoogle Scholar
- Gilbert DG, McClernon FJ, Rabinovich NE, Plath LC, Jensen RA, Meliska CJ (1998) Effects of smoking abstinence on mood and craving in men: influences of negative-affect-related personality traits, habitual nicotine intake and repeated measurements. Pers Individ Differ 25:399–423CrossRefGoogle Scholar
- Lorr M, McNair D (1984) Manual: Profile of Mood States. Educational and Industrial Testing Service, San Diego, CAGoogle Scholar
- Poltavski DV, Petros T (2006) Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits. Physiol Behav 85:833–843Google Scholar
- Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401Google Scholar
- Reeves D, Kane R, Winter K (1995) Automated Neuropsychological Assessment Metrics (ANAM): test administrators guide version 3.11. National Cognitive Recovery Foundation, San Diego, CAGoogle Scholar
- Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156:1931–1937PubMedGoogle Scholar